HOOKIPA Pharma Inc
Company Profile
Business description
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
Contact
350 Fifth Avenue
72nd Floor, Suite 7240
New YorkNY10118
USAT: +1 431 890-6360
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
87
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,781.90 | 8.90 | 0.10% |
| CAC 40 | 7,665.91 | 25.64 | -0.33% |
| DAX 40 | 23,909.61 | 123.61 | -0.51% |
| Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
| FTSE 100 | 8,760.96 | 37.95 | -0.43% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,369.73 | 96.27 | 0.47% |
| Nikkei 225 | 40,123.40 | 363.99 | -0.90% |
| NZX 50 Index | 12,636.28 | 33.46 | 0.27% |
| S&P 500 | 6,204.95 | 31.88 | 0.52% |
| S&P/ASX 200 | 8,552.40 | 10.10 | 0.12% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |